Top analyst says the tempest over drug prices will likely just die out without any major changes
Leerink’s Geoffrey Porges is taking a bullish view on large cap biopharma companies’ chances for the rest of the year.
After watching stocks suffer through the doldrums over the last two years, he cites a series of factors that could make the coming months more of a treat than a terror for biopharma investors. Financial forecasts have moderated to more achievable levels and there appears to be a better chance of some appealing, though fairly limited, beats to Wall Street consensus numbers.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.